-
02:39:19 AM

BLUE Stock News

01/18/23 8:00 PM
Nasdaq : BLUE
offeringhigh short
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
Goldman Sachs& Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting...
RHEA-AI
neutral
01/09/23 7:00 AM
Nasdaq : BLUE
high short
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
bluebird bio, Inc. today announced updates to be presented at the 41 st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT. “In 2022, bluebird bio emerged as a commercial stage gene therapy company, with a...
RHEA-AI
positive
01/05/23 8:00 AM
Nasdaq : BLUE
conferenceshigh short
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
bluebird bio, Inc. today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT. To access the live webcast of bluebird bio’ s presentation, please visit the“ Events& Presentations” page within the Investors& Media section...
RHEA-AI
neutral
01/03/23 8:00 AM
Nasdaq : BLUE
managementhigh short
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
bluebird bio, Inc. today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. “Joe’ s appointment, including his decades of legal and business development expertise in biotechnology and across the life sciences industry, solidifies and strengthens our management team as we continue our transition into a commercial stage...
RHEA-AI
very positive
12/19/22 7:30 AM
Nasdaq : BLUE
high short
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
bluebird bio, Inc. today announced that the U.S. Food and Drug Administration lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel for sickle cell disease. “We are very pleased to have addressed the FDA’ s questions and resolved the partial clinical hold,” said Richard Colvin, M.D., Ph.D., chief medical...
RHEA-AI
very positive
12/10/22 11:30 AM
Nasdaq : BLUE
high short
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
Today new and updated data from bluebird bio inc.’ s gene therapy programs in beta-thalassemia and sickle cell disease were presented at the 64 th American Society of Hematology Annual Meeting and Exposition. The ASH Annual Meeting is taking place December 10-13, 2022, in New Orleans and virtually. Today, with the first FDA approved gene therapy for...
RHEA-AI
neutral